Amgen-backed Seismic shakes up $121M financing for preclinical immunology programs

Seismic Therapeutic has secured a series B of significant magnitude, with $121 million pitched in by new investor Amgen Ventures in a round aimed at pushing two immunology programs into the clinic.

The series B was led by new investor Bessemer Venture Partners, with participation from Amgen Ventures and Codon Capital, Alexandria Venture Investments, Gaingels and GC&H. Existing investors Timothy A. Springer, Lightspeed Venture Partners, Polaris Partners, Boxer Capital, GV, Samsara BioCapital, and unnamed management members and founders also joined in.